Integrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experience
Open Access
- 30 April 2026
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119402
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature ReviewApplied Health Economics and Health Policy, 2025
- Clinical application of whole-genome sequencing of solid tumors for precision oncologyExperimental & Molecular Medicine, 2024
- Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumabJournal of Hepatology, 2023
- Whole-genome and transcriptome analysis enhances precision cancer treatment optionsAnnals of Oncology, 2022
- European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerAnnals of Oncology, 2022
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionCell, 2021
- Phase II trial design with growth modulation index as the primary endpointPharmaceutical Statistics, 2018
- Guidelines for Validation of Next-Generation Sequencing–Based Oncology PanelsThe Journal of Molecular Diagnostics, 2017
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015
- Structural Snapshots of Full-Length Jak1, a Transmembrane gp130/IL-6/IL-6Rα Cytokine Receptor Complex, and the Receptor-Jak1 HolocomplexStructure, 2011